Which has stronger earnings and valuation, JBIO or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$1.92 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is JBIO or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Parabilis Medicines N/A N/A N/A

Does the media prefer JBIO or PBLS?

In the previous week, Jade Biosciences had 3 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for Parabilis Medicines. Jade Biosciences' average media sentiment score of 0.99 beat Parabilis Medicines' score of 0.92 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACAD or JBIO?

In the previous week, Jade Biosciences had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.34 beat Jade Biosciences' score of 0.99 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, JBIO or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$1.92 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is JBIO or CELC more profitable?

Jade Biosciences' return on equity of -49.11% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Celcuity N/A -350.78% -41.54%

Does the media refer more to JBIO or CELC?

In the previous week, Jade Biosciences had 1 more articles in the media than Celcuity. MarketBeat recorded 6 mentions for Jade Biosciences and 5 mentions for Celcuity. Celcuity's average media sentiment score of 1.24 beat Jade Biosciences' score of 0.99 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, JBIO or DYN?

Jade Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jade Biosciences N/A N/A -$127.41M -$1.92 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A

Is JBIO or DYN more profitable?

Jade Biosciences' return on equity of -49.11% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jade Biosciences N/A -49.11% -45.62% Dyne Therapeutics N/A -64.30% -50.33%

Does the media favor JBIO or DYN?

In the previous week, Dyne Therapeutics had 28 more articles in the media than Jade Biosciences. MarketBeat recorded 34 mentions for Dyne Therapeutics and 6 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.99 beat Dyne Therapeutics' score of 0.23 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EWTX or JBIO?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Jade Biosciences N/A N/A -$127.41M -$1.92 N/A

Is EWTX or JBIO more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Jade Biosciences N/A -49.11% -45.62%

Does the media favor EWTX or JBIO?

In the previous week, Jade Biosciences had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 6 mentions for Jade Biosciences and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.55 beat Jade Biosciences' score of 0.99 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Jade Biosciences (JBIO) Competitors

$17.89 -1.25 (-6.53%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$17.90 +0.01 (+0.06%)

As of 09/11/2026 07:30 PM Eastern

Compare

JBIO vs. PBLS, ACAD, CELC, DYN, and EWTX

Should you buy Jade Biosciences stock or one of its competitors? Jade Biosciences's main competitors and comparable companies include Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), Dyne Therapeutics (DYN), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jade Biosciences compare to Parabilis Medicines?

Jade Biosciences (NASDAQ:JBIO) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Jade Biosciences had 3 more articles in the media than Parabilis Medicines. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for Parabilis Medicines. Jade Biosciences' average media sentiment score of 0.99 beat Parabilis Medicines' score of 0.92 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences presently has a consensus target price of $51.75, indicating a potential upside of 189.27%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.98%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jade Biosciences is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Parabilis Medicines' return on equity of 0.00% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Parabilis Medicines	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Summary

Jade Biosciences beats Parabilis Medicines on 6 of the 8 factors compared between the two stocks.

How does Jade Biosciences compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Jade Biosciences had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.34 beat Jade Biosciences' score of 0.99 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Jade Biosciences' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Jade Biosciences	N/A	-49.11%	-45.62%

ACADIA Pharmaceuticals has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.54
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals presently has a consensus target price of $34.36, indicating a potential upside of 23.47%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 189.27%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

ACADIA Pharmaceuticals beats Jade Biosciences on 11 of the 16 factors compared between the two stocks.

How does Jade Biosciences compare to Celcuity?

Jade Biosciences (NASDAQ:JBIO) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

63.3% of Celcuity shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Jade Biosciences' return on equity of -49.11% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Celcuity	N/A	-350.78%	-41.54%

Jade Biosciences has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Jade Biosciences currently has a consensus price target of $51.75, indicating a potential upside of 189.27%. Celcuity has a consensus price target of $154.55, indicating a potential upside of 85.20%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Jade Biosciences is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Celcuity is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Jade Biosciences had 1 more articles in the media than Celcuity. MarketBeat recorded 6 mentions for Jade Biosciences and 5 mentions for Celcuity. Celcuity's average media sentiment score of 1.24 beat Jade Biosciences' score of 0.99 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jade Biosciences beats Celcuity on 10 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Dyne Therapeutics?

Jade Biosciences (NASDAQ:JBIO) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Jade Biosciences has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Dyne Therapeutics had 28 more articles in the media than Jade Biosciences. MarketBeat recorded 34 mentions for Dyne Therapeutics and 6 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.99 beat Dyne Therapeutics' score of 0.23 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Jade Biosciences' return on equity of -49.11% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Jade Biosciences presently has a consensus target price of $51.75, indicating a potential upside of 189.27%. Dyne Therapeutics has a consensus target price of $32.17, indicating a potential upside of 76.64%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Jade Biosciences is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81

Jade Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Summary

Jade Biosciences beats Dyne Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Jade Biosciences compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Edgewise Therapeutics' return on equity of -39.01% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Jade Biosciences	N/A	-49.11%	-45.62%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

In the previous week, Jade Biosciences had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 6 mentions for Jade Biosciences and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.55 beat Jade Biosciences' score of 0.99 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics presently has a consensus target price of $50.33, suggesting a potential upside of 13.36%. Jade Biosciences has a consensus target price of $51.75, suggesting a potential upside of 189.27%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Jade Biosciences beats Edgewise Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JBIO vs. The Competition

Export

Metric	Jade Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-9.32	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.65	15.12	10.33	6.20
Net Income	-$127.41M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-10.10%	-4.34%	-3.32%	-2.35%
1 Month Performance	-24.86%	0.54%	-0.53%	-3.23%
1 Year Performance	132.34%	40.74%	23.51%	8.79%

Jade Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JBIO Jade Biosciences	2.2728 of 5 stars	$17.89 -6.5%	$51.75 +189.3%	+132.3%	$1.14B	N/A	N/A	55	News Coverage Analyst Downgrade
PBLS Parabilis Medicines	2.4188 of 5 stars	$40.75 +1.6%	$41.67 +2.2%	N/A	$5.03B	N/A	N/A	N/A	Positive News
ACAD ACADIA Pharmaceuticals	4.3857 of 5 stars	$27.86 -3.7%	$34.36 +23.3%	+17.9%	$4.80B	$1.07B	12.55	510	Positive News
CELC Celcuity	2.5964 of 5 stars	$96.43 +0.2%	$154.55 +60.3%	+52.0%	$4.72B	N/A	N/A	40	Positive News
DYN Dyne Therapeutics	3.094 of 5 stars	$24.95 -0.8%	$34.42 +37.9%	+38.5%	$4.66B	N/A	N/A	100	Analyst Forecast Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JBIO) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jade Biosciences (JBIO) Competitors

JBIO vs. PBLS, ACAD, CELC, DYN, and EWTX

How does Jade Biosciences compare to Parabilis Medicines?

Summary

How does Jade Biosciences compare to ACADIA Pharmaceuticals?

Summary

How does Jade Biosciences compare to Celcuity?

Summary

How does Jade Biosciences compare to Dyne Therapeutics?

Summary

How does Jade Biosciences compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jade Biosciences (JBIO) Competitors

JBIO vs. PBLS, ACAD, CELC, DYN, and EWTX

How does Jade Biosciences compare to Parabilis Medicines?

Does the media prefer JBIO or PBLS?

Do analysts rate JBIO or PBLS?

Is JBIO or PBLS more profitable?

Which has stronger earnings and valuation, JBIO or PBLS?

Summary

How does Jade Biosciences compare to ACADIA Pharmaceuticals?

Does the media favor ACAD or JBIO?

Which has more volatility and risk, ACAD or JBIO?

Is ACAD or JBIO more profitable?

Which has higher earnings & valuation, ACAD or JBIO?

Do insiders & institutionals have more ownership in ACAD or JBIO?

Do analysts recommend ACAD or JBIO?

Summary

How does Jade Biosciences compare to Celcuity?

Do institutionals and insiders have more ownership in JBIO or CELC?

Is JBIO or CELC more profitable?

Which has more volatility and risk, JBIO or CELC?

Do analysts recommend JBIO or CELC?

Which has better earnings & valuation, JBIO or CELC?

Does the media refer more to JBIO or CELC?

Summary

How does Jade Biosciences compare to Dyne Therapeutics?

Which has more risk and volatility, JBIO or DYN?

Do institutionals & insiders believe in JBIO or DYN?

Does the media favor JBIO or DYN?

Is JBIO or DYN more profitable?

Do analysts rate JBIO or DYN?

Which has better valuation and earnings, JBIO or DYN?

Summary

How does Jade Biosciences compare to Edgewise Therapeutics?

Is EWTX or JBIO more profitable?

Which has higher earnings & valuation, EWTX or JBIO?

Which has more volatility and risk, EWTX or JBIO?

Does the media favor EWTX or JBIO?

Do analysts recommend EWTX or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO vs. The Competition

Jade Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools